Morgan Stanley analyst Terence Flynn raised the firm’s price target on Biogen (BIIB) to $190 from $156 and keeps an Equal Weight rating on the shares. The firm sees the company’s “building” pipeline as the focus post the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $215 from $185 at Citi
- Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold
- Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating
- Biogen Earnings Call: Solid 2025, Cautious 2026 Outlook
- Biogen price target raised to $196 from $165 at BMO Capital